Executive Summary

Sirnaomics Ltd., a clinical-stage RNA therapeutics company, has released its 2025 annual report revealing a year marked by stringent financial discipline, substantial cost reductions, a qualified audit opinion, and ongoing uncertainties that may significantly impact the company’s share price. This report provides investors with a comprehensive overview of the company’s financial health, strategic direction, governance, and risk factors, with an emphasis on issues that may be price sensitive.

Financial Highlights and Key Developments

• Net Loss and Liquidity: Sirnaomics recorded a net loss of approximately US\$14.6 million and a net operating cash outflow of US\$9.2 million for the year ended December 31, 2025. As of that date, the Group had net current liabilities of US\$22.8 million, net liabilities of US\$24.5 million, and cash and cash equivalents of US\$13.5 million.
• Cost Reduction: The company achieved a >70% reduction in non-essential operating expenses, focusing resources on high-potential core assets (STP705/707/122G/125G) and validation of the PNP/GalAhead™ platforms. Organizational streamlining resulted in a concentrated workforce (37 employees as of year-end), with no adverse impact on core program progress.
• Equity Financing: Targeted equity financing in 2025 raised approximately US\$6.8 million (after adjustments for partial terminations of subscriptions), and a prior 2024 subscription added US\$7.5 million, extending the Group’s cash runway. However, most proceeds are earmarked for general corporate and working capital purposes.
• Audit Qualification and Material Uncertainty: The independent auditor issued a qualified opinion due to insufficient evidence regarding the fair value of a financial asset at FVTPL (relating to a fund investment subject to default and ongoing arbitration). There is a material uncertainty on the Group’s ability to continue as a going concern.
• Bank Borrowings: Total bank borrowings increased to US\$2.33 million, up from US\$405,000 in 2024, reflecting both secured and unsecured facilities, all classified as current liabilities due to repayable-on-demand clauses.
• No Revenue: The company did not generate any revenue in 2025, indicating ongoing reliance on external funding and shareholder equity.

Strategic and Operational Developments

• Clinical and Regulatory Pipeline: Key priorities for 2026 include:
  • Seeking further FDA guidance for STP705’s pivotal trials and advancing its medical aesthetics program.
  • Submitting the STP125G IND application and finalizing STP122G’s Phase II development plans.
  • Maintaining market transparency regarding progress and the distinctive capabilities of the PNP and GalAhead™ platforms.
• Commercial Readiness: Actively pursuing out-licensing of pipeline assets and forming technology partnerships to strengthen the cash position and accelerate RNAi therapeutics advancement.
• Corporate Governance and ESG: The Group restructured to a unified Chairman and CEO model for strategic alignment, enhanced risk management, and reported zero trial adverse events. There is a strong focus on transparency, stakeholder engagement, and ESG compliance.

Risk Factors & Price Sensitive Issues

• Qualified Audit Opinion – Financial Asset at FVTPL: The auditor could not obtain sufficient information to verify the fair value of a significant fund investment (Segregated Portfolio of TradArt Flagship Investment SPC) due to a potential default, lack of transparency on underlying assets, and ongoing arbitration. The inability to ascertain the asset’s value and the resulting qualified opinion is highly price sensitive and could affect investor confidence.
• Material Uncertainty Related to Going Concern: The company’s ability to continue as a going concern is dependent on maintaining minimal cash outflows and securing further financing. If management’s plans are not successful, there could be significant negative adjustments to asset values and possible reclassification of liabilities, which may negatively impact the share price.
• No Revenue and Ongoing Losses: The absence of revenue and continued net losses highlight the urgent need for successful clinical advancement, partnership deals, or further fundraising. Any delays or failures in these areas are price sensitive.
• Cash Runway & Capital Structure: While recent financings have extended the cash runway, the company remains reliant on external funding and must carefully manage liquidity to avoid financial distress.
• Regulatory & Pipeline Risk: Any delays in FDA engagement or clinical progress, especially in light of government shutdowns and the competitive RNA landscape, could materially impact the company’s prospects and valuation.
• Shareholder Structure: As of December 31, 2025, Dr. Poon Hung Fai and Quarmaceutical Limited control 16.44% of shares; the public float stands at 83.56%.

Other Noteworthy Information

• The Group did not pay dividends in 2025 and expects to retain all future earnings for growth and operations.
• No material litigation (other than the unresolved matter related to the investment fund) and no controlling shareholder as of 2025.
• Remuneration, equity incentive, RSU, and share option schemes remain in place to retain and incentivize staff.
• Major supplier concentration remains high, with the top supplier accounting for 57% of total purchases; no revenue was generated from customers in 2025.

Conclusion

Sirnaomics Ltd. remains at a critical juncture. While the company has demonstrated strong cost control and secured additional funding, the unresolved default and lack of transparency in a major fund investment, as well as ongoing losses and a material uncertainty regarding going concern, represent significant risks. Any negative developments in these areas, or failure to achieve clinical and commercial milestones, could materially impact the share price. Investors should monitor updates on the arbitration outcome, further financing plans, and clinical/regulatory progress closely.

Disclaimer

This article is for informational purposes only and is not investment advice. Investors should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions. The information herein is based on company disclosures and may be subject to change without notice. The writer assumes no responsibility or liability for any errors, omissions, or outcomes related to the use of this information.